Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery.

Journal of Cataract and Refractive Surgery

PubMedID: 16105620

Reis A, Birnbaum F, Hansen LL, Reinhard T. Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery. J Cataract Refract Surg. 2005;31(7):1437-40.
Two patients had uneventful phacoemulsification. After initial improvement, vision deteriorated because of cystoid macular edema (CME). In 1 patient, treatment with systemic nonsteroidal antiinflammatory drugs showed significant improvement in visual acuity but had to be discontinued because of side effects and a relapse of the disease. In the other patient, this therapy was not sufficient. Both patients were given valdecoxib, a cyclooxygenase-2 inhibitor. The new therapy was tolerated well and led to significant and stable improvement in visual acuity in both patients. To our knowledge, this is the first report of using a cyclooxygenase-2 inhibitor in the treatment of clinically significant CME.